C3N-02721
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 54.46406571
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.300
- COMPLEMENT+0.150
- PI3K_AKT_MTOR_SIGNALING+0.150
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.150
- XENOBIOTIC_METABOLISM+0.150
- BILE_ACID_METABOLISM+0.120
- INTERFERON_GAMMA_RESPONSE+0.110
- HEME_METABOLISM+0.080
- MITOTIC_SPINDLE+0.040
- SPERMATOGENESIS+0.040
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- MYC_TARGETS_V1-0.320
- PANCREAS_BETA_CELLS-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.310
- ANGIOGENESIS-0.300
- E2F_TARGETS-0.270
- CHOLESTEROL_HOMEOSTASIS-0.240
- TNFA_SIGNALING_VIA_NFKB-0.240
- GLYCOLYSIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-01799 | — | cohortA1 | 0.774 |
| 2 | BS_5PJCHF6V | Med | Medulloblastoma | 0.756 |
| 3 | TCGA-NJ-A4YQ-01A-11R-A262-07 | — | cohortA1 | 0.743 |
| 4 | MBCProject_5856_T0B_RNA | — | A | 0.736 |
| 5 | s0122234 | — | — | 0.724 |
| 6 | MNG1008 | — | — | 0.724 |
| 7 | ERR2208899 | — | — | 0.722 |
| 8 | MBCProject_1819_T2B_RNA | — | D | 0.722 |
| 9 | SRR2016932 | — | — | 0.721 |
| 10 | C3N-03212 | — | cohortA1 | 0.706 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.040 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.010 | Inavolisib | — uncovered |